Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VPA Expanded Cord Blood Stem Cells in Hematological Malignancies
NCT03885947Phase 1Completed
- Start
- Feb 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of valproic acid + expanded cord blood stem cells in hematological malignancy, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 3 more (2 arms). Primary endpoints: Number of Infusion Reaction at 42 days and Number of Graft Failure at 42 days. Started Feb 2019; status: completed.
02
Drugs
valproic acid + expanded cord blood stem cells
03
Conditions
hematological malignancyacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03885947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03885947.